Raymond James Financial Services Advisors Inc. lessened its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) by 23.6% in the third quarter, HoldingsChannel reports. The fund owned 50,277 shares of the company’s stock after selling 15,542 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Mirum Pharmaceuticals were worth $1,056,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in MIRM. Polar Capital Holdings Plc acquired a new position in Mirum Pharmaceuticals during the 1st quarter worth $21,441,000. First Light Asset Management LLC bought a new stake in shares of Mirum Pharmaceuticals in the 1st quarter worth $4,735,000. State Street Corp raised its stake in shares of Mirum Pharmaceuticals by 107.8% in the 2nd quarter. State Street Corp now owns 275,867 shares of the company’s stock worth $5,368,000 after buying an additional 143,123 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Mirum Pharmaceuticals by 323.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 121,808 shares of the company’s stock worth $2,370,000 after buying an additional 93,071 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Mirum Pharmaceuticals by 104.8% in the 2nd quarter. Northern Trust Corp now owns 176,766 shares of the company’s stock worth $3,440,000 after buying an additional 90,439 shares in the last quarter.
Analysts Set New Price Targets
MIRM has been the topic of a number of research reports. Raymond James dropped their price objective on Mirum Pharmaceuticals from $88.00 to $84.00 and set a “strong-buy” rating on the stock in a research note on Tuesday, January 10th. JPMorgan Chase & Co. dropped their price objective on Mirum Pharmaceuticals to $30.00 in a research note on Monday, November 28th. Citigroup cut their target price on Mirum Pharmaceuticals from $38.00 to $34.00 and set a “buy” rating on the stock in a research report on Thursday, November 10th. HC Wainwright boosted their target price on Mirum Pharmaceuticals from $68.00 to $69.00 and gave the stock a “buy” rating in a research report on Monday, November 14th. Finally, SVB Leerink cut their target price on Mirum Pharmaceuticals from $50.00 to $39.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 10th.
Insider Activity at Mirum Pharmaceuticals
Mirum Pharmaceuticals Trading Down 4.8 %
NASDAQ:MIRM opened at $21.25 on Friday. The firm has a market capitalization of $783.49 million, a price-to-earnings ratio of -18.97 and a beta of 1.29. Mirum Pharmaceuticals, Inc. has a 1-year low of $16.07 and a 1-year high of $30.55. The business’s fifty day moving average price is $19.37 and its 200 day moving average price is $21.81.
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Rating) last posted its quarterly earnings results on Wednesday, November 9th. The company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.03. The firm had revenue of $18.78 million for the quarter, compared to analyst estimates of $21.16 million. Mirum Pharmaceuticals had a negative return on equity of 99.78% and a negative net margin of 79.72%. Equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -4.01 earnings per share for the current year.
Mirum Pharmaceuticals Profile
Mirum Pharmaceuticals, Inc is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O’Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
- Get a free copy of the StockNews.com research report on Mirum Pharmaceuticals (MIRM)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.